Efficacy and Safety of Aspirin and Clopidogrel in the Atrial Fibrillation With Low or Moderate Stroke Risk

A phase 3 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 1500 participants.

Also called NCT02960126

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 1,500 participants (planned count) (from the registry)
Sponsor
Chuncheon Sacred Heart Hospital (from the registry)
Registry
  • NCT NCT02960126
Start date
(registry gives no type) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Not reported
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT02960126. Randomized; no masking; primary purpose treatment. Start 2016-11 (registry gives no type); primary completion 2020-10 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Efficacy and Safety of Aspirin and Clopidogrel in the Atrial Fibrillation With Low or Moderate Stroke Risk
Acronym
CESAC-AF
Intervention (Drug)
Aspirin
Intervention (Drug)
Clopidogrel
Lead sponsor
Chuncheon Sacred Heart Hospital (class: other)

Record details

Record id
cardio:ct-nct02960126
Content hash
1596664a8206eda2dde133bc839401567c1244febbe49084ae295ac973b1a4be